Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $26.1 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $26.1 million, up 28.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.3 million (up 21.57% YoY), and the FY2025 annual result was $91.6 million, up 13.86% from the prior year.
• Depreciation & Amortization (CF) advanced to $26.1 million in Q1 2026 per SUPN's latest filing, from $25.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $26.1 million in Q1 2026 and troughed at $18.8 million in Q4 2024.
• A 5-year average of $21.7 million and a median of $21.4 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) surged 226.22% in 2022, then declined 13.06% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $20.8 million in 2022, then gained by 3.97% to $21.7 million in 2023, then dropped by 13.06% to $18.8 million in 2024, then soared by 32.75% to $25.0 million in 2025, then advanced by 4.46% to $26.1 million in 2026.
• Business Quant data shows SUPN's Depreciation & Amortization (CF) at $26.1 million in Q1 2026, $25.0 million in Q4 2025, and $24.8 million in Q3 2025.